The Food and Drug Administration yesterday approved a new antibiotic to treat adults with community-acquired bacterial pneumonia. The antibiotic, Xenleta, received priority review under an FDA Safety and Innovation Act designation for drug products intended to treat serious or life-threatening infections. About 1 million people are hospitalized with community-acquired pneumonia annually in the United States. “For managing this serious disease, it is important for physicians and patients to have treatment options,” said Ed Cox, M.D., director of FDA’s Office of Antimicrobial Products. “This approval reinforces our ongoing commitment to address treatment of infectious diseases by facilitating the development of new antibiotics.”  
 

Headline
Erica Taylor, M.D., orthopedic surgeon and vice president of health equity at Duke Health, shares how the organization’s frontline liaison network is helping…
Headline
The Department of Health and Human Services Oct. 26 announced that more than 250 hospitals have signed its voluntary pledge related to hospital efforts on…
Headline
There are now 1,136 confirmed measles cases in Pennsylvania this year amid the state’s outbreak, the Pennsylvania Department of Health announced Oct. 9. Of…
Chairperson's File
Public
Hospitals and health systems — traditionally focused on acute care — are increasingly becoming more involved in primary care. There is tremendous value for…
Headline
The deadline to apply for the inaugural AHA Age-Friendly Healthcare Impact Award is Sept. 25. The award, created by the AHA and The John A. Hartford Foundation…
Headline
The Substance Abuse and Mental Health Services Administration announced Sept. 18 that it awarded $42.3 million in grants to states and territories to support…